Income Statement
SANA BIOTECHNOLOGY, INC.
SANA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
250.32 | 272.72 | 293.14 | 272.56 | 356.91 |
|
Research & Development
|
131.98 | 217.56 | 268.82 | 285.89 | 248.63 |
|
Selling, General & Administrative
|
44.30 | 64.04 | 73.30 | 71.56 | 50.41 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-250.32 | -272.72 | -293.14 | -272.56 | -356.91 |
|
Non-Operating Income
|
- | - | - | - | -0.98 |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
2.31 | -4.51 | -0.05 | -0.67 | 0.31 |
|
Income Before Tax
|
- | - | - | - | -355.93 |
|
Income Tax Expense
|
- | - | - | - | 0.00 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-244.17 | -266.76 | -283.26 | -269.48 | -355.93 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-250.32 | -272.72 | -293.14 | -272.56 | -356.91 |
|
Earnings Per Share (Basic)
|
-0.96 | -1.16 | -1.46 | -1.43 | - |
|
Diluted EPS
|
-0.96 | -1.16 | -1.46 | -1.43 | - |
|
Weighted Average Shares
|
253.23 | 230.89 | 194.54 | 188.34 | - |
|
Diluted Weighted Avg Shares
|
253.23 | 230.89 | 194.54 | 188.34 | - |
|
Comprehensive Income
|
-244.15 | -266.69 | -278.99 | -272.44 | -357.32 |